Beacon Investment Advisory Services Inc. Has $37.84 Million Stake in Insulet Co. (NASDAQ:PODD)

Beacon Investment Advisory Services Inc. cut its position in shares of Insulet Co. (NASDAQ:PODD) by 2.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 162,584 shares of the medical instruments supplier’s stock after selling 3,972 shares during the quarter. Insulet makes up about 1.6% of Beacon Investment Advisory Services Inc.’s portfolio, making the stock its 19th largest holding. Beacon Investment Advisory Services Inc.’s holdings in Insulet were worth $37,841,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its stake in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the period. International Assets Investment Management LLC bought a new position in Insulet during the second quarter worth $32,000. UMB Bank n.a. grew its holdings in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, CVA Family Office LLC increased its stake in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PODD. UBS Group raised their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Canaccord Genuity Group raised their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler lifted their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Stock Down 0.1 %

Insulet stock opened at $266.78 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $18.71 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The firm’s 50-day simple moving average is $244.40 and its 200 day simple moving average is $214.14.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.